FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008385633> ?p ?o ?g. }

• W2008385633 endingPage "41" @default.
• W2008385633 startingPage "36" @default.
• W2008385633 abstract "<i>Background:</i> Oxaliplatin has become one of the major cytotoxic agents for the treatment of gastrointestinal tumors. As a result, several cases of the so-called oxaliplatin-associated hypersensitivity reaction have been documented. <i>Patients and Methods:</i> We have retrospectively evaluated and characterized these reactions in our patient group by reviewing the files of 1,224 patients exposed to an oxaliplatin-containing regimen in order to provide useful clinical information for diagnosis and management. <i>Results:</i> Three hundred and eight (308) patients who have never been exposed to platinum compounds developed symptoms compatible with a reaction to oxaliplatin that was verified by manifestation of at least similar symptoms on rechallenging. The reactions occurred after the first 5 courses, with a median course number of 9 (range 1–24). These reactions could be distinguished as (1) mild reactions occurring in 195 (63%) patients manifesting with itching and small area erythema either during treatment or within the next hours, and (2) severe reactions occurring in 113 (37%) patients within minutes of drug infusion manifesting with diffuse erythroderma, facial swelling, chest tightness, bronchospasm and changes in blood pressure. Oxaliplatin withdrawal was not required in patients with a mild reaction. Forty-eight (42%) patients having a severe reaction with appropriate premedication and prolongation of the infusion duration could tolerate 2–4 subsequent courses. For the remaining 65 (58%) patients, oxaliplatin withdrawal was inevitable because of the very severe reactions occurring on rechallenging. In addition, 3 patients presented with thrombocytopenia and 3 others with hemolytic anemia, all reversible upon oxaliplatin discontinuation. <i>Conclusions:</i> Hypersensitivity reactions to oxaliplatin are underestimated. Although the reactions are not frequent during first courses, in extensively pretreated patients, they may become a serious problem. In the majority of patients, drug discontinuation might not be necessary. In patients manifesting a severe reaction, re-exposure to oxaliplatin should be considered only if the patient can tolerate the reaction and there has been clinical benefit from this therapy. Physicians and nursing staff should be aware of the risk and be well prepared." @default.
• W2008385633 created "2016-06-24" @default.
• W2008385633 creator A5005090351 @default.
• W2008385633 creator A5016553757 @default.
• W2008385633 creator A5017462015 @default.
• W2008385633 creator A5018500204 @default.
• W2008385633 creator A5028022669 @default.
• W2008385633 creator A5033556587 @default.
• W2008385633 creator A5041448475 @default.
• W2008385633 creator A5053612880 @default.
• W2008385633 creator A5061872212 @default.
• W2008385633 creator A5065339449 @default.
• W2008385633 creator A5066138388 @default.
• W2008385633 creator A5066381417 @default.
• W2008385633 creator A5077706957 @default.
• W2008385633 creator A5078192662 @default.
• W2008385633 creator A5087643777 @default.
• W2008385633 creator A5090540906 @default.
• W2008385633 date "2008-11-26" @default.
• W2008385633 modified "2023-10-16" @default.
• W2008385633 title "Clinical Features of Hypersensitivity Reactions to Oxaliplatin: A 10-Year Experience" @default.
• W2008385633 cites W1835851824 @default.
• W2008385633 cites W1910585037 @default.
• W2008385633 cites W1965274356 @default.
• W2008385633 cites W1966985559 @default.
• W2008385633 cites W1976759995 @default.
• W2008385633 cites W1983134727 @default.
• W2008385633 cites W1996167718 @default.
• W2008385633 cites W2000574965 @default.
• W2008385633 cites W2000983373 @default.
• W2008385633 cites W2008776993 @default.
• W2008385633 cites W2015326709 @default.
• W2008385633 cites W2032146688 @default.
• W2008385633 cites W2037504446 @default.
• W2008385633 cites W2044309123 @default.
• W2008385633 cites W2051667118 @default.
• W2008385633 cites W2067511454 @default.
• W2008385633 cites W2070957637 @default.
• W2008385633 cites W2076366897 @default.
• W2008385633 cites W2078860792 @default.
• W2008385633 cites W2086126432 @default.
• W2008385633 cites W2117634047 @default.
• W2008385633 cites W2139406527 @default.
• W2008385633 cites W2145347666 @default.
• W2008385633 cites W2150139826 @default.
• W2008385633 cites W2157183678 @default.
• W2008385633 cites W2161782921 @default.
• W2008385633 cites W2162313061 @default.
• W2008385633 cites W2171232394 @default.
• W2008385633 cites W2182035713 @default.
• W2008385633 cites W2285157229 @default.
• W2008385633 cites W2310042498 @default.
• W2008385633 cites W2311663614 @default.
• W2008385633 cites W2416235537 @default.
• W2008385633 cites W2765278021 @default.
• W2008385633 doi "https://doi.org/10.1159/000178163" @default.
• W2008385633 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19033714" @default.
• W2008385633 hasPublicationYear "2008" @default.
• W2008385633 type Work @default.
• W2008385633 sameAs 2008385633 @default.
• W2008385633 citedByCount "77" @default.
• W2008385633 countsByYear W20083856332012 @default.
• W2008385633 countsByYear W20083856332013 @default.
• W2008385633 countsByYear W20083856332014 @default.
• W2008385633 countsByYear W20083856332015 @default.
• W2008385633 countsByYear W20083856332016 @default.
• W2008385633 countsByYear W20083856332017 @default.
• W2008385633 countsByYear W20083856332018 @default.
• W2008385633 countsByYear W20083856332019 @default.
• W2008385633 countsByYear W20083856332020 @default.
• W2008385633 countsByYear W20083856332021 @default.
• W2008385633 countsByYear W20083856332022 @default.
• W2008385633 countsByYear W20083856332023 @default.
• W2008385633 crossrefType "journal-article" @default.
• W2008385633 hasAuthorship W2008385633A5005090351 @default.
• W2008385633 hasAuthorship W2008385633A5016553757 @default.
• W2008385633 hasAuthorship W2008385633A5017462015 @default.
• W2008385633 hasAuthorship W2008385633A5018500204 @default.
• W2008385633 hasAuthorship W2008385633A5028022669 @default.
• W2008385633 hasAuthorship W2008385633A5033556587 @default.
• W2008385633 hasAuthorship W2008385633A5041448475 @default.
• W2008385633 hasAuthorship W2008385633A5053612880 @default.
• W2008385633 hasAuthorship W2008385633A5061872212 @default.
• W2008385633 hasAuthorship W2008385633A5065339449 @default.
• W2008385633 hasAuthorship W2008385633A5066138388 @default.
• W2008385633 hasAuthorship W2008385633A5066381417 @default.
• W2008385633 hasAuthorship W2008385633A5077706957 @default.
• W2008385633 hasAuthorship W2008385633A5078192662 @default.
• W2008385633 hasAuthorship W2008385633A5087643777 @default.
• W2008385633 hasAuthorship W2008385633A5090540906 @default.
• W2008385633 hasConcept C121608353 @default.
• W2008385633 hasConcept C126322002 @default.
• W2008385633 hasConcept C141071460 @default.
• W2008385633 hasConcept C2776042228 @default.
• W2008385633 hasConcept C2776694085 @default.
• W2008385633 hasConcept C2778088044 @default.
• W2008385633 hasConcept C2778300832 @default.
• W2008385633 hasConcept C2779121184 @default.

• next